Pump.fun becomes the first platform on Solana to reach a cumulative revenue of 1 billion dollars
Odaily reported that since its launch at the beginning of 2024, Pump.fun has accumulated approximately $1.08 billions in revenue, becoming the first platform on the Solana blockchain to surpass $1 billions in revenue. According to DefiLlama data, the platform's revenue in 2024 was $321.3 millions, in 2025 it reached $664 millions, and so far in 2026 it stands at $98.3 millions.
For comparison, the decentralized trading aggregator Jupiter in the Solana ecosystem has accumulated $401.3 millions in revenue since its launch, while the automated market maker Raydium has accumulated $126.9 millions in revenue.
Pump.fun uses almost all protocol revenue for PUMP token buybacks. On March 11, the platform executed a buyback of approximately $1.25 millions, accounting for 99.93% of the previous day's revenue. Since the buyback plan was launched, the platform has cumulatively bought back about $323.4 millions worth of PUMP tokens, representing 28.8% of the circulating supply. Nevertheless, the current trading price of PUMP remains below the initial issue price of $0.004, and is still far from its historical high of $0.0088.
Additionally, public domain records show that Pump.fun has established subdomains pointing to Ethereum, Base, BSC, and Monad, and has removed Solana's geographic identifier from its X account. Previously, Pump.fun added support for tokens created on platforms such as Raydium and Meteora in its mobile app, and acquired the cross-chain trading terminal Vyper.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Applied Digital shares surge as Q1 revenue quadruples
October 8 - ** Data center service provider Applied Digital (APLD.O) saw its stock rise 3.57% in pre-market trading to $24.66 ** The company’s Q1 revenue (link) surged more than fourfold to $341.9 millions, far surpassing analyst estimates of $133.8 millions ** Northland Capital Securities noted that APLD’s revenue and cash flow should increase significantly in the coming years as contracted data center capacity becomes operational and starts generating income ** Net loss attributable to common shareholders widened from $18.5 millions (7 cents/share) a year ago to $221 millions (76 cents/share) ** According to data compiled by London Stock Exchange Group (LSEG), the average rating from 17 analysts covering the stock is “Buy”, with a median target price of $70.00, representing an upside of about 194% from the current price ** Year-to-date, the stock is down about 2.9%, while the Nasdaq Index .IXIC is up 18.5% over the same period. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation and provides it only as a convenience. Reuters assumes no liability for any damage or loss resulting from the use of automated translation.)
WTI crude oil rises above $91 per barrel, up 3.02% intraday
WTI crude oil rose above $91 per barrel for the first time since October 2, with a daily increase of 3.02%.
AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) TROP2 ADC receives approval for new indication in China
According to information from Zhihu Finance APP, AstraZeneca (AZN.US) and Daiichi Sankyo (DSNKY.US) have announced that Datroway® (generic name: datopotamab deruxtecan for injection) has been approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not suitable for PD-1/PD-L1 inhibitor therapies. Datopotamab deruxtecan is an antibody-drug conjugate (ADC) targeting TROP2, developed with proprietary technology by Daiichi Sankyo, and jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.
Abu Dhabi National Oil Company invites bids for crude oil cargo shipments
Trader: Abu Dhabi National Oil Company issued a tender this week to sell crude oil for December loading or January delivery.
Crypto prices
More
